PRINCETON, N.J., December 02, 2021--(BUSINESS WIRE)--NJ Biopharmaceuticals LLC (d/b/a NJ Bio), an expert provider of chemistry and biopharmaceutical services specializing in bioconjugation, custom synthesis, flow chemistry, and process development has expanded its footprint at its state-of-the-art laboratory and headquarters located at 350 Carter Road, Princeton from 35,000 square feet to approximately 79,000 square feet.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211202005142/en/
NJ Bio Expands it's Footprint to Occupy the Entire Main Campus Facility at 350 Carter Road in Princeton, New Jersey. (Photo: Business Wire)
This expansion, which will include GMP manufacturing capabilities for bioconjugates and small molecules, is a significant milestone for NJ Bio. NJ Bio will soon be able to support the development and GMP manufacturing of Antibody Drug Conjugates (ADCs) to meet the growing and urgent demand for clinical assets in this field. NJ Bio is aggressively hiring synthetic organic, bioconjugation and oligonucleotide chemists as well as analytical and QA/QC personnel to increase capacity and build up its GMP manufacturing capabilities. NJ Bio will also continue to operate its facility in Bristol, PA, with plans to further expand its GMP manufacturing capabilities.
"On behalf of NJ Bio employees and the Board of Directors, I am excited to announce the achievement of this significant milestone in our journey to providing expanded services and resources to support our clients’ clinical study programs," said Nareshkumar Jain, Ph.D., President and CEO of NJ Bio. "NJ Bio was granted the Best Contract Research Provider Award at the 8th World ADC Awards in October 2021 for being an outstanding partner to our clients, delivering high value for their research and development needs. Now, we aim to become an even more integrated partner to deliver on their clinical programs. We are laser-focused on setting up our state-of-the-art GMP manufacturing suites to become operational in 2022. This expansion will enable us to manufacture GMP grade payload-linkers, drug candidates, and antibody-drug conjugates for phase 1 - 3 clinical studies for our clients".
This expansion of resources and facilities is an important step to transition NJ Bio from being a Contract Research Provider to a Contract Development and Manufacturing Organization.
For additional information, visit www.njbio.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211202005142/en/